Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus

University of Miami

Status and phase

Withdrawn

Phase 4

Conditions

Living Donor Kidney Transplants Patients

Treatments

Drug: Tacrolimus, Myfortic and Sirolimus

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01038505

20090531

Details and patient eligibility

About

The investigators center has also analyzed data over the last 7 years from deceased donor (DD) and living donor (LD) kidney transplant recipients who were randomized into 3 immunosuppressive arms between 2000 and 2001. Thus the goal of the investigators study is to reduce the toxic effects of traditional immunosuppressive regimens involving high-dose calcineurin inhibitor agents by comparing low-dose TAC-MYF with low-dose TAC and de novo SRL regimens. In order to minimize exposure to TAC, the investigators center has previously shown favorable outcomes using combination Thymoglobulin and Zenapax (Daclizumab) for anti-lymphocyte induction in the investigator population of patients.

Full description

A total of 150 randomized patients divided into 2 arms: 75 patients will be randomized to receive TAC-SRL, and 75 patients to receive TAC-MYF.

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Non-HLA identical living donor kidney transplant patients

Exclusion criteria

Patient has previously received or is receiving an organ transplant other than a kidney.
Patient is receiving an ABO incompatible donor kidney.
Recipient or donor is known seropositive for human immunodeficiency (HIV) or Hepatitis C virus, or Hepatitis B virus antigenemia.
Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully, or carcinoma in-situ of the cervix that has been treated successfully.
Patients with significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range at our center.
Patient has uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable medical condition that could interfere with study objectives.
Patient is currently participating in another clinical trial of an investigational drug in the 30 days prior to transplant.
Patient will be receiving any immunosuppressive agent other than those prescribed in the study.
Patient is unable to take medications orally or via nasogastric tube by the morning of the second day following completion of the transplant procedure (i.e., skin closure).
Patient is receiving or may require Warfarin, Fluvastatin, or herbal supplements during the study.
Concurrent use of Astemizole, Pimozide, Cisapride, Terfenadine, or Ketoconazole.
Patient has a known hypersensitivity to Tacrolimus, Thymoglobulin®, IL-2 receptor inhibitor monoclonal antibodies, Rapamune, Myfortic®, or corticosteroids.
Patient is pregnant or lactating.
Patients with a screening/baseline (or within 96 hours of transplant) total white blood cell count <4000/mm3; platelet count <100,000/mm3; fasting triglycerides >400 mg/dl (>4.6 mmol/L); fasting total cholesterol >300 mg/dl (>7.8 mmol/L); fasting HDL-cholesterol <30 mg/dl; fasting LDL-cholesterol >200 mg/dl.
Patient is unlikely to comply with the visits scheduled in the protocol.
Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.
If Tacrolimus cannot be instituted for longer than 5 days postoperatively.